251 related articles for article (PubMed ID: 12045122)
1. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency.
Stockley RA; Bayley DL; Unsal I; Dowson LJ
Am J Respir Crit Care Med; 2002 Jun; 165(11):1494-8. PubMed ID: 12045122
[TBL] [Abstract][Full Text] [Related]
2. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ).
Hill AT; Campbell EJ; Bayley DL; Hill SL; Stockley RA
Am J Respir Crit Care Med; 1999 Dec; 160(6):1968-75. PubMed ID: 10588615
[TBL] [Abstract][Full Text] [Related]
3. Effect of expectoration on inflammation in induced sputum in alpha-1-antitrypsin deficiency.
Gompertz S; Hill AT; Bayley DL; Stockley RA
Respir Med; 2006 Jun; 100(6):1094-9. PubMed ID: 16257194
[TBL] [Abstract][Full Text] [Related]
4. Airways inflammation in chronic bronchitis: the effects of smoking and alpha1-antitrypsin deficiency.
Hill AT; Bayley DL; Campbell EJ; Hill SL; Stockley RA
Eur Respir J; 2000 May; 15(5):886-90. PubMed ID: 10853853
[TBL] [Abstract][Full Text] [Related]
5. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
Schmid ST; Koepke J; Dresel M; Hattesohl A; Frenzel E; Perez J; Lomas DA; Miranda E; Greulich T; Noeske S; Wencker M; Teschler H; Vogelmeier C; Janciauskiene S; Koczulla AR
Int J Chron Obstruct Pulmon Dis; 2012; 7():687-96. PubMed ID: 23055718
[TBL] [Abstract][Full Text] [Related]
6. Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy.
Zamora NP; Pla RV; Del Rio PG; Margaleff RJ; Frias FR; Ronsano JB
Ann Pharmacother; 2008 May; 42(5):640-6. PubMed ID: 18413692
[TBL] [Abstract][Full Text] [Related]
7. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients.
Griese M; Latzin P; Kappler M; Weckerle K; Heinzlmaier T; Bernhardt T; Hartl D
Eur Respir J; 2007 Feb; 29(2):240-50. PubMed ID: 17050563
[TBL] [Abstract][Full Text] [Related]
8. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis.
Hill AT; Campbell EJ; Hill SL; Bayley DL; Stockley RA
Am J Med; 2000 Sep; 109(4):288-95. PubMed ID: 10996579
[TBL] [Abstract][Full Text] [Related]
9. [Long-term substitution in homozygous alpha 1-antitrypsin deficiency. Effect of the proteinase-antiproteinase equilibrium in plasma and sputum].
Braun J; Welle S; van Wees J; Winterhoff R; Wood WG; Dalhoff K; Wiessmann KJ
Dtsch Med Wochenschr; 1990 Jun; 115(23):889-94. PubMed ID: 2191843
[TBL] [Abstract][Full Text] [Related]
10. Prolastin aerosol therapy and sputum taurine in cystic fibrosis.
Cantin AM; Berthiaume Y; Cloutier D; Martel M
Clin Invest Med; 2006 Aug; 29(4):201-7. PubMed ID: 16986483
[TBL] [Abstract][Full Text] [Related]
11. Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency.
Tirado-Conde G; Lara B; Miravitlles M
Ther Adv Respir Dis; 2008 Feb; 2(1):13-21. PubMed ID: 19124355
[TBL] [Abstract][Full Text] [Related]
12. Assessment of airway neutrophils by sputum colour: correlation with airways inflammation.
Stockley RA; Bayley D; Hill SL; Hill AT; Crooks S; Campbell EJ
Thorax; 2001 May; 56(5):366-72. PubMed ID: 11312405
[TBL] [Abstract][Full Text] [Related]
13. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.
Tonelli AR; Brantly ML
Ther Adv Respir Dis; 2010 Oct; 4(5):289-312. PubMed ID: 20650978
[TBL] [Abstract][Full Text] [Related]
14. Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. The American-Italian AATD Study Group.
Gottlieb DJ; Luisetti M; Stone PJ; Allegra L; Cantey-Kiser JM; Grassi C; Snider GL
Am J Respir Crit Care Med; 2000 Dec; 162(6):2069-72. PubMed ID: 11112116
[TBL] [Abstract][Full Text] [Related]
15. The BLT1 Inhibitory Function of α-1 Antitrypsin Augmentation Therapy Disrupts Leukotriene B4 Neutrophil Signaling.
O'Dwyer CA; O'Brien ME; Wormald MR; White MM; Banville N; Hurley K; McCarthy C; McElvaney NG; Reeves EP
J Immunol; 2015 Oct; 195(8):3628-41. PubMed ID: 26371243
[TBL] [Abstract][Full Text] [Related]
16. Alpha-1 antitrypsin (AAT) deficiency - what are the treatment options?
Modrykamien A; Stoller JK
Expert Opin Pharmacother; 2009 Nov; 10(16):2653-61. PubMed ID: 19827990
[TBL] [Abstract][Full Text] [Related]
17. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
18. Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release.
Nita I; Hollander C; Westin U; Janciauskiene SM
Respir Res; 2005 Jan; 6(1):12. PubMed ID: 15683545
[TBL] [Abstract][Full Text] [Related]
19. High-density lipoproteins potentiate α1-antitrypsin therapy in elastase-induced pulmonary emphysema.
Moreno JA; Ortega-Gomez A; Rubio-Navarro A; Louedec L; Ho-Tin-Noé B; Caligiuri G; Nicoletti A; Levoye A; Plantier L; Meilhac O
Am J Respir Cell Mol Biol; 2014 Oct; 51(4):536-49. PubMed ID: 24787644
[TBL] [Abstract][Full Text] [Related]
20. Alpha-1 antitrypsin augmentation therapy.
Wewers MD; Crystal RG
COPD; 2013 Mar; 10 Suppl 1():64-7. PubMed ID: 23527997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
